ADME / Tox

Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Although a high level of market fragmentation typically […]

The Current Status of Non-Biopharma Drug Discovery By Dr John Comley Screening centres in academic institutions and non-profit organisations have, over the past decade, become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides in cancer and phenotypic screens, […]

Rules For Drug Discovery: Can simple property criteria help you to find a drug? By Dr Matthew Segall The years since the publication of Lipinski’s Rule of Five (Ro5) (1) in 1997 have seen the growth of a minor industry, dedicated to generating new ‘rules’ for drug discovery. Fuelled by what Kenny and Montanari have […]

Healthcare and Life Sciences undergoing disruptive change by linked data and semantic technologies By Hans Constandt From early days the sharing of knowledge has been one of the main forces driving science and innovation. Yet latterly, the pharmaceutical industry with its fear of loss of intellectual property has stalled the engine that has given so […]

Partnering with the right CRO is a winning strategy for companies big and small By Dr Davide Molho The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen the biopharmaceutical industry gradually become more willing to look externally and embrace the concept of outsourcing as it looks for new […]

Realising The Genome’s Potential In The Context Of The Living Cell By Dr Amr Abid A decade ago, with the completion of the Human Genome Project (HGP), scientists had the long-awaited sequence of the human genome in hand. Once decoded, this invaluable source of data was anticipated to reveal the pathology underlying a host of […]

Adoption Of High Content Screening At High Throughput Screening Laboratories By William Downey and Dr Jennifer Hartigan Over the past five years, a majority of HTS laboratories have adopted high content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, cell-based assays and high content screening technologies have become more widespread. […]

An Automated Approach To Solving Pharma’s Cardiac Toxicity Conundrum By Dr Walter Westerink, Dr Nuria Piñeiro Costas, and Beppy van de Waart The pharmaceutical industry is facing ever-growing difficulties in developing new drugs and bringing them to market (1,2). Many factors stand in the way of R&D productivity, not least of which are shrinking budgets. […]

Carbon-14 Labelled API Manufacturing By Dr Sean L. Kitson and Dr David Speed Carbon-14 labelled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. The short supply and escalating price of carbon-14 […]

Fragment Library Design – The Evolution Of Fragment Based Lead Discovery By Dr Edward Zartler, Dr Chris Swain and Simon Pearce With the growing need to streamline the drug discovery process, screening against fragment libraries rather than drug-like molecules has become increasingly adopted as an integral part of many drug discovery programmes. However, success depends […]